Abstract
THE principal biochemical defect associated with Parkinsonism is a marked decrease in the dopamine and serotonin content of the brain1. L-Dopa, a precursor of dopamine, has been found to help patients suffering from this disease, presumably by increasing the concentration of dopamine in the brain2.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bernheimer, H., Birkmayer, O., and Hornykiewicz, Klin. Wochenschaft, 20, 1056 (1961).
Cotzias, G. C., Van Woert, M. D., and Schitter, L. M., New Engl. J. Med., 276, 374 (1967).
Hidaka, H., Nagatsu, T., Takeya, K., Takeuchi, T., Suda, H., Kojiri, K., Matsuzake, M., and Umezawa, H., J. Antibiotics, 22, 228 (1966).
Nagatsu, T., Hidaka, H., Kuzuya, H., Takeya, K., Umezawa, H., Takeuchi, T., and Suda, H., Biochem. Pharmacol., 19, 35 (1970).
Terazawa, F., and Kameyama, M., Jap. Circulation J., 35, No. 349 (1971).
Okada, T., Fujita, T., Ota, O., Shinoda, T., Hidaka, H., Nagatsu, T., Takeuchi, T., and Umezawa, H., Igaku No Ayumi, 76, 495 (1971).
Anton, A. H., and Sayre, D. F., J. Pharmacol. Exp. Ther., 138, 360 (1962).
Anton, A. H., and Sayre, D. F., J. Pharmacol. Exp. Ther., 145, 326 (1964).
Wise, C. D., Anal. Biochem., 19, 2517 (1967).
Weissbach, H., Smith, T. E., Daly, J. W., Witkop, B., and Udenfriend, S., J. Biol. Chem., 235, 1160 (1960).
Udenfriend, S., Weissbach, H., and Brodie, B. B., Methods of Biochemical Analysis, 95 (Interscience, New York, 1958).
Ng, K. Y., Chase, T. N., Colburn, R. W., and Kopin, I. J., Science, 170, 76 (1970).
Thoa, N. B., Eccleston, D., and Axelrod, J., J. Pharmacol. Exp. Ther., 169, 68 (1969).
Bertler, A., Flack, B., and Owman, C., Acta Physiol. Scand., 63, Suppl. 239, 1 (1964).
Neff, N. H., Barret, R. E., and Costa, E., Europ. J. Pharmacol., 5, 348 (1969).
Lichtenstiger, W., Mutner, U., and Langemann, H., J. Neurochem., 14, 489 (1967).
Fuxe, K., and Ungerstedt, U., J. Pharmac. Pharmacol., 19, 335 (1967).
Iversen, L. L., in Advances in Biochemical Pharmacology, 2 (edit. by Costa, E., and Ciacobini, E.) (Raven Press, New York, 1970).
Shaskan, E. G., and Snyder, S. H. J., Pharmacol. Exp. Ther., 175, 404 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
HIDAKA, H. Fusaric (5-Butylpicolinic) Acid, an Inhibitor of Dopamine β-Hydroxylase, affects Serotonin and Noradrenaline. Nature 231, 54–55 (1971). https://doi.org/10.1038/231054a0
Received:
Issue Date:
DOI: https://doi.org/10.1038/231054a0
This article is cited by
-
Recent Computational Insights into the Oxygen Activation by Copper-Dependent Metalloenzymes
Topics in Catalysis (2022)
-
Fusaric acid induces a notochord malformation in zebrafish via copper chelation
BioMetals (2015)
-
Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453)
Drugs in R & D (2011)
-
Peripheral and central short-term effects of fusaric acid, a DBH inhibitor, on tryptophan and serotonin metabolism in the rat
Journal of Neural Transmission (1986)
-
Synthesis and pharmacological activity of fusaric acid and its derivatives
Pharmaceutical Chemistry Journal (1978)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.